The aim of this study was to determine and compare the added prognostic value of screening tools, geriatric assessment (GA) components, and GA summaries to clinical information for overall survival (OS) in older patients with cancer. METHODS: A screening and a 10-item GA were systematically performed in patients ≥70 years old with cancer. Cox regression analyses were conducted to evaluate the added prognostic value for OS of screening tools, GA, and GA summaries to clinical information (age, stage, and tumor type) in 2 cohorts (A and B). Cox models were compared on the basis of the Akaike information criterion and the concordance probability estimate. The 2 cohorts for the analyses were similar but independent. RESULTS: A complete case analysis was available for 763 patients (median age, 76 years) in cohort A and for 402 patients (median age, 77 years) in cohort B. In both cohorts, most individual GA components were independent prognostic factors for OS. Nutritional status (assessed with the Mini Nutritional Assessment Short Form) and functional status (assessed with the Instrumental Activities of Daily Living) consistently displayed a strong capacity to predict OS. Less consistent results were found for screening tools. GA summaries performed the best in comparison with the screening tools and the individual GA components. CONCLUSIONS: Most individual GA components, especially nutritional status and functional status, are prognostic factors for OS in older patients with cancer. GA summaries provide more prognostic information than individual GA components but only moderately improve the prognostic baseline model with clinical information.
INTRODUCTION
Epidemiologic research has predicted a significant increase in older patients with cancer in the coming decades.
1,2 Because important treatment and outcome variations have been reported and because of the heterogeneity within this population and the lack of evidence-based treatment guidelines, international oncologic organizations such as the International Society of Geriatric Oncology and the European Organisation for Research and Treatment of Cancer have recommended that some form of comprehensive geriatric assessment (CGA) be mandatory to guide oncologic treatment decisions. 3, 4 CGA is currently the gold standard for evaluating the global health status and clinical frailty level of individuals, and it is defined as a multidimensional, interdisciplinary diagnostic process focusing on determining an older person's medical, psychosocial, and functional capability so that a coordinated and integrated plan can be developed for treatment and long-term follow-up. 5 In the general (nononcologic) geriatric population, CGA-guided treatment plans have been shown to improve overall survival (OS), quality of life, and functional status and decrease the risk of hospitalization and nursing home placement. [6] [7] [8] [9] [10] When applied to patients with cancer, a CGA has been shown to identify previously unknown health problems, to predict treatment-related toxicity and oncologic outcomes (including OS), and to influence cancer treatment decisions. [11] [12] [13] However, the majority of studies of CGA in the older population with cancer have focused on the implementation of systematic geriatric screening and geriatric assessment (GA), the first 2 steps of the CGA process. 5, 8 Several studies have identified items within the GA itself (eg, functional status, [14] [15] [16] nutritional
Cancer September 15, 2018 status, [14] [15] [16] [17] [18] and mental health [14] [15] [16] ) that are independent predictors of mortality.
To select patients who would benefit from GA, a number of geriatric screening tools have been developed, such as Geriatric 8 (G8), Vulnerable Elders Survey 13, and the Flemish version of the Triage Risk Screening Tool (fTRST). Some of these screening tools can also provide important information about treatment-related toxicity, the risk of functional decline, and OS. 4, 19, 20 However, GA does not yield a validated summary score, so it remains difficult to precisely quantify a patient's global health status. For this reason, some attempts to summarize and categorize GA results have been proposed in geriatric oncology, but the included elements and cutoffs are arbitrary and do not capture the complexity of GA and the aging process itself. 21 Despite this, the most consistent finding is an association between mortality and a GA summary score (eg, frail/vulnerable/fit). 16, [22] [23] [24] [25] The aim of this study was to determine and compare the added prognostic value for OS of screening tools, individual GA components, and 2 GA summaries to a baseline model of clinical information in older patients with cancer. In clinical practice, this is helpful to better individualize prognostic information.
MATERIALS AND METHODS

Design
To determine and compare the added value of screening, individual GA components, and 2 GA summaries (henceforth, GA components and GA summaries are together called geriatric information) to a baseline model of clinical information for predicting OS, this study integrated 2 different study cohorts, cohort A 4 and cohort B, 26 which were extensively reported previously (see Fig. 1 ). Both study cohorts came from prospective, multicenter, observational cohort studies. Patients with cancer aged 70 years or older were approached for inclusion during a hospital visit at diagnosis or at disease progression/relapse when a treatment decision had to be made. In the study of cohort A (n = 937; October 2009 to July 2011), inclusion was limited to the following 6 tumor types: breast, colorectal, ovarian, lung, and prostate cancer and hematologic malignancies. This study focused on the implementation of a systematic geriatric screening and assessment. 4 In the study of cohort B (n = 1550; August 2011 to July 2012), patients with all tumor types (except for nonmelanoma skin cancer) and hematologic malignancies were included. The focus of this study was geriatric recommendations based on GA results. 26 In both studies, patients
were assessed in a uniform manner: study cohort A came from 2 Belgian hospitals (Universitair Ziekenhuis Brussel and Universitaire Ziekenhuizen Leuven), 4 and study cohort B came from 6 academic hospitals and 3 nonacademic hospitals spread all over Belgium. 26 The analysis for cohort B was limited to patients of Universitair Ziekenhuis Brussel and Universitaire Ziekenhuizen Leuven and to patients with breast, colorectal, lung, prostate, and ovarian cancer so that it would correspond to the hospitals and studied tumor types in cohort A. Patients with a hematologic malignancy were excluded from the analysis presented in this study because TNM staging was not applicable for most of these tumors (and so could not be integrated into prognostic models). The complete case analysis was taken into account: this left 763 patients in cohort A and 402 patients in cohort B.
Screening and GA
At the baseline, a trained health care worker performed a screening and GA for all patients, as previously reported. 4, 26 Patients were assessed with 2 geriatric screening tools, the G8 and the fTRST, with each evaluating the presence of a geriatric risk profile (see Supporting Table 1 ). The G8 includes 7 items from the Mini Nutritional Assessment (MNA) and 1 age-related item. The total score varies from 0 to 17. A G8 score ≤ 14 indicates the presence of a geriatric risk profile. 27, 28 fTRST is a 5-item screening tool with a range of 0 to 6. 4, 29, 30 Within the oncologic population, a score ≥ 1 indicates the presence of a geriatric risk profile. 4 Also, the Eastern Cooperative Oncology Group (ECOG) performance status (PS), which is not age-specific, was evaluated. 31 The GA included 10 components based on the 2014 International Society of Geriatric Oncology recommendation guideline for GA 13 : social data with the living situation, functional status as assessed by Katz's Activities of Daily Living (ADL) 32 and Lawton's Instrumental Activities of Daily Living (IADL), 33 the fall history during the last year, 34 fatigue as assessed by the MobilityTiredness Test (MOB-T), 35 mental status as assessed by the Mini Mental State Examination (MMSE) 36 and the 15-item Geriatric Depression Scale, 37 nutritional status as assessed by the Mini Nutritional Assessment Short Form (MNA-SF), 38 comorbidities as assessed by the Charlson Comorbidity Index (CCI), 39 and a polypharmacy assessment.
40
GA Summaries
In this study, the 10-item GA was a GA summary that integrated the results of every GA component mentioned
Cancer September 15, 2018 previously and thus captured a multidimensional GA, evaluating the global health of the older patient with cancer as a whole. All components were integrated dichotomously. However, it did not calculate a global GA end score, and no cutoff was defined to differentiate between fitness and frailty.
The 41 (see Supporting Table 2 ). In detail, the following score categories are included: 0 to 2 (severely frail), 3 to 4 (frail), 5 to 6 (vulnerable), 7 to 8 (slightly vulnerable), and 9 to 10 (fit).
Statistical Analysis
The baseline model of clinical information consisted of age, stage, and tumor type. Age was categorized with 3 levels: 70 to 74, 75 to 79, and ≥80 years. Comparisons of continuous data were performed with the Student t test and the Wilcoxon test as appropriate, whereas comparisons of categorical data were performed with the chi-square test and/or with Fisher's exact test as appropriate. The statistical significance level used was .05.
The follow-up time was defined as the time from the first GA assessment to the last follow-up for all censored patients. Median, minimum, and maximum follow-up times are reported.
The Kaplan-Meier method was used to describe survival, and log-rank and Wilcoxon tests were used to compare different groups.
Univariate Cox proportional hazards regression analyses were conducted to evaluate the prognostic value of patient and clinical characteristics, screening tools, and geriatric information. Multivariate analyses were performed as well for the analyses with screening tools and geriatric information to adjust for clinical information. OS was calculated from the date of the GA to the date of death from any cause or last follow-up for censored patients. Results were considered significant if P was < .05. Cancer September 15, 2018 We performed Cox proportional hazards regression analyses to build multiple prognostic models. To assess the contributions of screening tools and geriatric information, each component was added separately to the baseline model of clinical information. The proportional hazards assumption was tested and not violated. Multicollinearity was also assessed with the variance inflation factor and was not present (variance inflation factor < 3).
The discriminatory ability of each prognostic model was assessed with the concordance probability estimate (CPE). 42 The interpretation of the CPE is identical to the widely used but less robust c-index and indicates the proportion of all pairs of patients whose predicted survival times are correctly ordered among all patients who can actually be ordered. In other words, a model with a higher CPE corresponds to a model with better predictive accuracy.
The Akaike information criterion (AIC) assesses the global fit of a model: the lower the AIC value, the better the model fit. The global fits of the Cox models were compared by means of the difference between the AIC values of the baseline model and the extended model (ΔAIC). A higher ΔAIC value corresponded to a more explanatory and informative model. The screening tools and all individual GA components were assessed as dichotomous variables. The LOFS was assessed as a categorical variable. All analyses were performed with SAS 9.3 (SAS Institute, Cary, North Carolina) and SPSS 17.0 (SPSS, Chicago, Illinois).
The added prognostic value of screening tools and geriatric information was tested on 2 different consecutive large cohorts of patients to evaluate the consistency between the results. The aim was not to perform a formal validation because we did not develop a prognostic tool.
RESULTS
Patient Population
In cohort A, a total of 788 patients with carcinoma were considered for data analysis, and in cohort B, a total of 491 patients were considered. A complete case analysis was available for 763 patients in cohort A and for 402 patients in cohort B (see Fig. 1 ).
In cohort A, the median age was 76 years (range, 70-95 years), and 67.8% were women; in cohort B, the median age was 77 years (range, 70-95 years), and 66.7% were women. In cohorts A and B, the most prevalent carcinomas were breast and colorectal cancer (48.8% and 24.4%, respectively, in cohort A and 42.0% and 32.8%, respectively, in cohort B). At the moment of inclusion in the study, 63.7% and 71.4% had newly diagnosed cancer in cohorts A and B, respectively, whereas 36.3% had disease progression or relapse in cohort A, and 28.6% had disease progression or relapse in cohort B. More details about the patient demographics and clinical characteristics are listed in Table 1 . Significant differences between the 2 cohorts were present for the tumor type (P = .019), oncologic setting (P = .008), and surgical treatment (P = .006).
After a median follow-up of 61.4 months (range, 0.7-75.6 months) in cohort A and 45.7 months (range, 7.3-54.5 months) in cohort B, there was no significant difference (P = .496) in OS between the 2 cohorts. The median survival times were 33.2 months (range, 0.09-75.6 months; 471 deaths) and 37.6 months (range, 0.16-54.5 months; 214 deaths), respectively.
The results of the screening and GA are listed in Table 2 . The 2 cohorts were similar according to the results of the G8, the ECOG PS, and most individual GA components, although there were significant differences for fTRST (P < .001), ADL (P < .001), IADL (P = .01), and MMSE (P < .001).
Prognostic Value for OS of Patient and Clinical Characteristics, Screening Tools, and Geriatric Information
The following variables were analyzed: patient and clinical characteristics (sex, age, stage, and tumor type), screening tools (G8, fTRST, and ECOG PS), individual GA components (living situation, ADL, IADL, fall history, MOB-T, MMSE, 15-item Geriatric Depression Scale, MNA-SF, CCI, and polypharmacy), and 2 GA summaries (10-item GA and LOFS).
The univariate analyses showed that all variables were prognostic for OS in both cohorts with the exception of living situation in cohort A and with the exception of living situation and fTRST in cohort B (see Tables 3 and 4) . Kaplan-Meier curves with associated log-rank tests are shown in Supporting Figure 1 . The analyses with screening tools and geriatric information were repeated and adjusted for clinical information. This showed that all variables were prognostic for OS with the exception of living situation and comorbidities in cohort A and with the exception of the G8, living situation, and polypharmacy in cohort B (Table 4) .
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Comparison of the Performance of Models Extended With Screening Tools and Geriatric Information
Detailed results for cohorts A and B are summarized in Table 5 . A visual overview of the discriminatory ability of the models can be found in Figure 2 . The baseline model of clinical information had a good discriminatory ability with CPEs of 0.728 and 0.750, respectively. The addition of the screening tools improved the discriminatory ability (CPE) and the fit of the model (ΔAIC) in comparison with the baseline model in cohort A. The G8 model improved the baseline model the most among the screening tools with a CPE of 0.747 and a ΔAIC value of 57.26. In contrast, in cohort B, the G8 model decreased the quality of the baseline model (ΔAIC, -0.10) while improving the discriminatory ability (CPE, 0.753) slightly. The ECOG PS model had the best performance in cohort B with a CPE of 0.762 and a ΔAIC value of 16.80.
The models extended with the 10 individual GA components did not always improve the discriminatory ability, whereas the fit of the model always improved with the exception of the addition of comorbidities as measured by the CCI in cohort A. Nutritional status as measured by the MNA-SF (CPE, 0.756; ΔAIC, 34.11), followed by functional status as measured by the IADL (CPE, 0.754; ΔAIC, 31.89), improved the baseline model the most in cohort A in terms of both CPE and ΔAIC. In cohort B, the CPE was improved the most by the addition of nutritional status as measured by the MNA-SF (CPE, 0.772) followed by fatigue as measured by the MOB-T (CPE, 0.771), whereas the fit of the model was improved the most by the addition of the IADL (ΔAIC, 10.00) followed by the MOB-T (ΔAIC, 9.84) and then the MNA-SF (ΔAIC, 8.78).
The 10-item GA improved the baseline model with a CPE of 0.755 and a ΔAIC value of 57.72 in cohort A and with a CPE of 0.775 and a ΔAIC value of 23.58 in cohort B. In comparison, the LOFS improved the baseline model with a CPE of 0.745 and a ΔAIC value of 37.82 in cohort A and with a CPE of 0.755 and a ΔAIC value of 34.81 in cohort B.
DISCUSSION
As outlined in the introduction, several GA components have been shown to be independent predictors of mortality in older patients with cancer. This study shows in 2 separate cohorts that most individual GA components are prognostic factors for OS in patients with cancer independently of clinical information (age, stage, and tumor type) in a heterogeneous oncologic population. The nutritional status and the IADL consistently displayed a strong individual prognostic capacity in comparison with the other GA components. Although previous research has shown inconsistent results about which GA components are prognostic in populations with various stages and tumor types, the 2 aforementioned GA components have often been found to be prognostic for OS. 4, 10 Besides the living situation in both cohorts, comorbidity as measured by the CCI in cohort A and polypharmacy as a proxy for comorbidity in cohort B were not prognostic factors when adjustments were made for clinical information. The lack of a prognostic impact of comorbidities might be related to an already poor prognosis for patients with certain tumor characteristics and/or to limitations of the CCI instrument.
In this study, we also examined the added prognostic value of screening tools and geriatric information for predicting OS by comparing the performance of multiple extended prognostic models with respect to a baseline model of clinical information (age, tumor type, and stage). This method also allowed us to get a better view of the relative importance of the individual GA components and the GA as a whole (ie, the 10-item GA). Cancer September 15, 2018 In contrast to other studies, we compared the performance of prognostic models with the AIC, which is a more sensitive measure than concordance indices (ie, CPE and c-index) for model selection. The AIC shows that the nutritional status and the IADL have a high added value to clinical information in comparison with the other GA components (ΔAIC), and this is not surprising because both were strong prognostic factors in Cancer September 15, 2018 cohort A and cohort B (hazard ratio). Furthermore, the AIC results indicate that the models integrating and summarizing different components of GA (10-item GA and LOFS) perform better than the individual GA components. The 10-item GA had the best performance in cohort A and the second best performance in cohort B after the LOFS. These GA summaries capture more of the multidimensional process of aging, so it is not surprising that they perform better than individual GA components. The prognostic value of the LOFS, a GA summary score, was demonstrated for the first time in this study. The added value of the LOFS in addition to clinical information was consistent in the 2 cohorts and was higher than the added value of the best individual GA components in both cohorts. The LOFS seems to be an interesting tool because it has a good prognostic value in addition to clinical information and it summarizes the results of the GA in a single semicontinuous score, which has the advantage of simplicity of interpretation, which is necessary for daily practice.
Although similar results were observed in both cohorts for most prognostic individual GA components and the ECOG PS screening tool, less consistent results were found for some of the other individual GA components and the 2 geriatric screening tools (G8 and fTRST).
The conflicting results of the G8 are especially remarkable when clinical information is taken into account. The G8 showed a poor prognostic contribution in cohort B in contrast to the results in cohort A, where the G8 added almost as much prognostic information as the 10-item GA. The majority of the patients in both cohorts had breast cancer or colorectal cancer; however, there were significantly more colorectal cancer diagnoses in cohort B, although there was no significant difference in OS between the 2 cohorts. Because malnutrition is more prevalent with colorectal cancer and the G8 consists of 7 questions from the MNA questionnaire, it is possible that the prognostic information provided by both variables overlap, and this might have contributed to the lack of an added value of the G8 in cohort B. The other variables included in the models (ie, stage and G8 scores) did not differ between the cohorts and so do not explain the different results for the prognostic value of the G8.
Patients in cohort B more often had colorectal cancer (as discussed previously), a new diagnosis, and surgery; more had a geriatric risk profile according to the fTRST (but not according to the G8); they were more dependent for the ADL and the IADL; and they more often had an abnormal score for cognition. This indicates that patients in cohort B might have been more vulnerable than those in cohort A, though as mentioned previously, this did not influence survival but might have influenced the prognostic value of certain aspects of geriatric information in addition to clinical information. Of course, other confounding factors should be taken into account with respect to the heterogeneity of the studied populations, some of which are discussed further at the end of the discussion.
Until now, we have discussed the calculated hazard ratios of the individual parameters and the performance of the extended models according to the AIC values. With the AIC values, models can be ranked, and this allows the selection of the best model. However, the AIC does not provide a measure of performance as such because it might select the best model out of a series of poor models. The CPE, on the other hand, does provide an interpretable measure of performance.
The baseline models showed good discrimination in both cohorts (CPE for cohort A, 0.728; CPE for cohort B, 0.750) and were able to correctly order the survival times of 2 randomly chosen patients approximately 3 out The 95% CI is less than 1 (significant).
Cancer September 15, 2018 of 4 times. Only small differences in CPE values were observed between the better models, and the ranking of models based on the more sensitive AIC and CPE yielded different patterns, although the model extended with the 10-item GA was always the best or second best model in accordance with results based on AIC. However, the concordance indices (here CPEs) are insensitive for detecting improvements in model performance when a parameter is added to a model with already important predictors. 43 According to the CPEs, the best models in our study (ie, the 10-item GA model and the MNA model) improved the overall performance of the model of clinical information by approximately 2.5%, so a significant number of deaths were still not explained by the aforementioned parameters.
Several studies have evaluated the association between GA and mortality in patients with cancer for different purposes. 15, 18, 44 In accordance with our first analyses, most studies have focused on the most prognostic individual GA components to improve the identification of patients with an increased mortality risk for appropriate interventions. From these analyses, it can be concluded that GA has some prognostic value, but because of inconsistent results, no specific recommendations can be made to guide treatment decision making. In contrast to some of these studies, we have not shown that certain GA components predict mortality, but we rather have shown that most GA components do. This is the case in 2 separate cohorts. Others have focused on the prediction of early death or have aimed to develop nomograms, for example. The prognosis or the estimation of life expectancy is crucial in the treatment decision-making process. However, none of these studies have focused on the additional value of the GA as a whole in estimating life expectancy before the start of treatment. In this study, we quantified how much the GA as a whole improves the prognosis beyond clinical information, and no prior study has done this before.
When our results are being interpreted, some considerations need to be made. Our study population The 95% CI is less than 1 (significant).
Cancer September 15, 2018 was heterogeneous in terms of oncologic parameters: there were different tumor types, different staging systems, different oncologic (molecular) subtypes, different treatments, different susceptibilities to treatment, and so forth. Many of these oncologic factors can have an important impact on OS, and they are not captured in this study. Ideally, the impact of screening tools and geriatric information should be evaluated in tumor populations having exactly the same tumor and treatment characteristics and having differences only in geriatric parameters. It is extremely difficult to obtain large samples sizes with such criteria. Moreover, findings in such populations are relevant only for those highly selected populations and would need to be evaluated separately in many other specific tumor settings; this is not realistic. It could be possible that in such homogeneous populations, the incremental value of screening tools and geriatric information is larger than approximately 2.5% because in our current heterogeneous population, these effects might be diluted by major differences in oncologic prognoses. On the other hand, our heterogeneous population in both cohorts can be an advantage because it is representative of a large cancer population. Moreover, OS prediction is far from the only goal of GA. GA is important for estimating the risk of treatment-induced toxicity, 41, 42 for detecting previously unknown health problems, 9 and for allowing directed geriatric interventions that can improve therapy compliance, quality of life, and outcomes.
In conclusion, most individual GA components, especially nutritional status as assessed by the MNA-SF and functional status as assessed by the IADL, are independent prognostic factors for OS in older patients with cancer. GA summaries provide more prognostic information than individual GA components but only moderately improve the prognostic baseline model with clinical information. 
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